| Literature DB >> 27422264 |
Hui Xu1, Zhengchen You2, Zhonghua Wu1, Liang Zhou3, Jianhong Shen4, Zhikai Gu5.
Abstract
WY14643 is a selective agonist of peroxisome proliferator-activated receptor-α (PPAR-α) with neuroprotective and neurotrophic effects. The aim of this study was to evaluate the effects of WY14643 on cognitive impairments induced by scopolamine, a muscarinic acetylcholine receptor antagonist. We conducted different behavior tests including the Y-maze, Morris water maze, and passive avoidance test to measure the cognitive functions of C57BL/6J mice after scopolamine and WY14643 treatment. It was found that WY14643 injection significantly attenuated the scopolamine-induced cognitive impairments in these behavioral tests. Moreover, WY14643 treatment significantly enhanced the expression of brain-derived neurotrophic factor (BDNF) signaling cascade in the hippocampus. The usage of both PPAR-α inhibitor GW6471 and BDNF system inhibitor K252a fully prevented the memory-enhancing effects of WY14643. Therefore, these findings suggest that WY14643 could improve the scopolamine-induced memory impairments, and these effects are mediated by the activation of PPAR-α and BDNF system, thereby exhibiting a cognition-enhancing potential.Entities:
Keywords: Brain-derived neurotrophic factor; Memory; Scopolamine; WY14643; cAMP response element-binding protein
Mesh：
Substances：
Year: 2016 PMID： 27422264 DOI： 10.1007/s11064-016-2002-1
Source DB: PubMed Journal: Neurochem Res ISSN： 0364-3190 Impact factor: 3.996